FDA approves LivaNova aura6000 for obstructive sleep apnea
LivaNova said the US Food and Drug Administration granted premarket approval for its aura6000 System to treat adult patients with moderate to severe obstructive sleep apnea, marking a new entrant in the hypoglossal nerve stimulation market. The approval, dated March 18, 2026, covers adults with an apnea-hypopnea index of 15 to 65 who have failed, can’t tolerate, or aren’t eligible for standard treatments such as positive airway pressure, oral appliances, or pharmacotherapy. In the FDA’s PMA database, the device is listed as PMA P250013. LivaNova is also positioning aura6000 as the first US-approved hypoglossal nerve stimulation therapy without a complete concentric collapse contraindication or warning, and without a required pre-implant drug-induced sleep endoscopy. (accessdata.fda.gov)
Why it matters: For veterinary professionals, this is mainly a market and regulatory signal rather than a clinical one. It shows how neuromodulation platforms are continuing to expand into chronic airway disorders, and it reinforces the FDA’s willingness to clear implantable devices backed by randomized controlled data. The approval was supported by LivaNova’s OSPREY trial, which met primary safety and efficacy endpoints, with 12-month topline data showing a 65% responder rate, a 68% median reduction in apnea-hypopnea index, and no serious device- or procedure-related adverse events reported in the study updates. More broadly, it fits a wider FDA pattern in neuromodulation: for example, Nia Therapeutics recently received Breakthrough Device Designation for a fully implantable, closed-loop neurostimulation system for episodic memory loss after traumatic brain injury, based on early data showing a 19% recall improvement in a sham-controlled study. (investor.livanova.com)
What to watch: Next comes commercialization planning, payer uptake, and FDA review of LivaNova’s proposed next-generation, MRI-compatible version, which the company says it hopes to launch in the first half of 2027. The broader neuromodulation pipeline is also worth watching, including earlier-stage systems such as Nia’s, which is planning an IDE filing in 2026. (nasdaq.com)